Takeda presented promising data on its ulcerative colitis and Crohn’s disease drug Entyvio at the World Congress of Gastroenterology at ACG2017, Oct. 13 to Oct. 18 in Orlando, Fla. The data suggests ...
Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in ...
(RTTNews) - Takeda (TAK) said that the U.S. Food and Drug Administration has approved a subcutaneous or SC administration of Entyvio (vedolizumab) for maintenance therapy in adults with moderately to ...
Credit: Takeda. Entyvio for SC use is expected to be available by the end of October 2023. The Food and Drug Administration (FDA) has approved the subcutaneous (SC) administration of Entyvio ® ...
This clinical brief was sponsored by Takeda Pharmaceuticals U.S.A., Inc,. This information is exclusively for Payer Formulary Committees or other similar entities (groups of individuals that evaluate ...
OSAKA, Japan & CAMBRIDGE, Mass., February 19, 2026--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO ® ...
Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO ® (vedolizumab) can offer the possibility of clinical remission for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results